GoodRx Releases List of 30 Heart Medications Under $30
The cheapest medication on the list is hydrochlorothiazide at $4.55.
heart pills © bmarya83 - stock.adobe.com
The prescription cost-saving service GoodRx released today a list of 30 of the most common heart drugs that will be available to customers for under $30. The coupon codes will work at more than 70,000 pharmacies nationwide.
Cardiovascular disease currently affects almost half of Americans.
Some of the drugs available at the new rates are lisinopril, an ACE inhibitor, for $9.29; carvedilol, a beta blocker, for $10.68; and atorvastatin, a statin, for $10.10.
GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits, according to their recent report, The GoodRx Effect.
“Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD, Medical Editor at GoodRx in a press release.
Private Equity in Healthcare: Colonoscopy Prices Soar While Care Remains the Same
July 11th 2025Private equity acquisitions have increased rapidly across all aspects of healthcare, with gastroenterology practices experiencing the highest share. In the U.S., approximately 13% of gastroenterologists work in practices owned by private equity groups.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
